Dr. Yu on Moderate Hypofractionation in Prostate Cancer

James B. Yu, MD
Published: Monday, May 01, 2017


James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses moderate hypofractionation replacing the current standard of care for patients with prostate cancer.

Moderate hypofractionation could potentially be adopted, replacing standard fractionation, if there are a couple more years of data.

Many academics have the opinion that moderate hypofractionation is the new standard therapy but additionally, many will also prefer to wait for more data to accrue, discusses Yu.
 
SELECTED
LANGUAGE

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses moderate hypofractionation replacing the current standard of care for patients with prostate cancer.

Moderate hypofractionation could potentially be adopted, replacing standard fractionation, if there are a couple more years of data.

Many academics have the opinion that moderate hypofractionation is the new standard therapy but additionally, many will also prefer to wait for more data to accrue, discusses Yu.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x